The PHD3 (Prolyl Hydroxylase Domain-containing protein 3) antibody is a research tool used to detect and study the PHD3 enzyme, also known as EGLN3. which belongs to the EGLN family of oxygen-sensing prolyl hydroxylases. PHD3 plays a critical role in cellular responses to oxygen availability by regulating the stability of hypoxia-inducible factors (HIFs). Under normoxic conditions, PHD3 hydroxylates specific proline residues on HIF-α subunits (e.g., HIF-1α), marking them for proteasomal degradation via the von Hippel-Lindau (VHL) ubiquitin ligase complex. This process is suppressed under hypoxia, allowing HIF-α accumulation and activation of genes involved in angiogenesis, metabolism, and survival. Beyond HIF regulation, PHD3 is implicated in diverse physiological and pathological processes, including apoptosis, inflammation, and metabolic reprogramming. Researchers use PHD3 antibodies in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess its expression, localization, and interactions in tissues or cultured cells. Dysregulation of PHD3 has been linked to cancers, ischemic diseases, and metabolic disorders, making it a potential therapeutic target. Commercial PHD3 antibodies are typically validated for specificity using knockout controls or siRNA-mediated silencing. Suppliers like Novus Biologicals, Cell Signaling Technology, and Abcam offer monoclonal or polyclonal versions, often with species reactivity spanning human, mouse, and rat.